Europe Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (Generic Drugs and Branded Drugs), Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), and Application (HIV, Hepatitis, Virus Influenza, Herpes, and Other Applications), and Country
Market Introduction
Antiviral therapy is one of the most exciting branches of virology. These therapies are based on several strategies—direct-acting antivirals target viral proteins, enzymes, or nucleic acids; passive antibodies neutralize circulating viruses; and several other antivirals target cellular proteins or processes essential for viral replication.
Get more information on this report :
Market Overview and Dynamics
The Europe anti-viral therapies market is expected to reach US$ 21,122.66 million by 2027 from US$ 11,401.67 million in 2019. The market is anticipated to grow at a CAGR of 8.1% during 2020–2027. The growth of the market is attributed to the increasing prevalence of viral diseases and outbreak of COVID-19 pandemic, surging R&D expenditures by pharmaceutical companies, and rising government support for research activities and clinical trials. However, high cost of drug development obstructs the growth of the market to a certain extent.
Key Market Segments
In terms of type, the branded drugs segment accounted for a larger share of the Europe anti-viral therapies market in 2019. In terms of mechanism of action, the nucleotide polymerase inhibitors segment accounted for the largest share of the market in 2019. In terms of application, the HIV segment accounted for the largest share of the Europe anti-viral therapies market in 2019.
Major Sources and Companies Listed
Several major primary and secondary sources associated with the Europe anti-viral therapies market report are the World Health Organization (WHO), International Trade Administration (ITA),European Federation of Pharmaceutical Industries and Associations (EFPIA), International Health Regulation (IHR),Association of the British Pharmaceutical Industry, National AIDS Trusts (NAT), and others.
Reasons to Buy Report
- It provides understanding of the Europe anti-viral therapies market landscape and identifies anti-viral therapies market segments that are most likely to guarantee a strong return.
- It guides stay ahead of the race by comprehending the ever-changing competitive market landscape
- It helps efficiently plan merger and acquisition, and partnership deals in the anti-viral therapies market in Europe by identifying market segments with the most promising probable sales
- It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of the market performance of various segments.
- It provides revenue forecast of the market based on various segments for the period from 2019 to 2027.
EUROPE ANTI-VIRAL THERAPIES MARKET SEGMENTATION
By Type
- Branded Drugs
- Generic Drugs
By Mechanism of Action
- Nucleotide Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Application
- HIV
- Hepatitis
- Virus Influenza
- Herpes
- Others
By Country
- Germany
- UK
- France
- Italy
- Spain
Company Profiles
- AbbVie Inc.
- GlaxoSmithKline plc
- AstraZeneca
- F. HOFFMANN-LA ROCHE LTD
- Johnson and Johnson Services, Inc.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Anti-viral therapies Market – By Type
1.3.2 Europe Anti-Viral Therapies Market – By Mechanism of Action
1.3.3 Europe Anti-Viral Therapies Market– By Application
1.3.4 Europe Anti-Viral Therapies Market – By Country
2. Europe Anti-Viral Therapies Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Anti-Viral Therapies Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Anti-Viral Therapies Market - North America PEST Analysis
4.3 Expert Opinion
4.4 Expert Opinion
5. Europe Anti-Viral Therapies Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Increasing R&D Expenditures in Pharmaceutical Companies
5.1.2 Rising Government Support for Research Activities and Clinical Trials
5.2 Market Restraints
5.2.1 High Cost of Drug Development
5.3 Market Opportunities
5.3.1 Strong Pipeline of Anti-Viral Drugs
5.4 Future Trends
5.4.1 Growing Emphasis on Launching Anti-Viral Agents
5.5 Impact analysis
6. Anti-Viral Therapies Market – Europe Analysis
6.1 Europe Anti-Viral Therapies Market Revenue Forecasts and Analysis
7. Europe Anti-Viral Therapies Market Analysis and Forecasts To 2027 – By Type
7.1 Overview
7.2 Europe Anti-Viral Therapies Market, By Type 2019 & 2027 (%)
7.2.1 Europe Anti-Viral Therapies Market Revenue and Forecasts to 2027, By Type (US$ Mn)
7.3 Generic Drugs
7.3.1 Overview
7.3.2 Europe Generic Drugs Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Branded Drugs
7.4.1 Overview
7.4.1.1 Europe Branded Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
8. Europe Anti-Viral Therapies Market Analysis – By Mechanism of Action
8.1 Overview
8.2 Europe Anti-Viral Therapies Market, By Mechanism of Action 2019-2027 (%)
8.2.1 Europe Anti-Viral Therapies Market Revenue and Forecasts to 2027, By Mechanism of Action (US$ Mn)
8.3 Nucleotide Polymerase Inhibitor
8.3.1 Overview
8.3.2 Europe Nucleotide Polymerase Inhibitor Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Reverse Transcriptase Inhibitors
8.4.1 Overview
8.4.2 Europe Reverse Transcriptase Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Protease Inhibitors
8.5.1 Overview
8.5.2 Europe Protease Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
9. Europe Anti-Viral Therapies Market Analysis and Forecasts To 2027 – By Application
9.1 Overview
9.2 Europe Anti-Viral Therapies Market, By Application 2019 & 2027 (%)
9.2.1 Europe Anti-Viral Therapies Market Revenue and Forecasts to 2027, By Application (US$ Mn)
9.3 HIV
9.3.1 Overview
9.3.2 Europe HIV Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Hepatitis
9.4.1 Overview
9.4.2 Europe Hepatitis Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Herpes
9.5.1 Overview
9.5.2 Europe Herpes Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Influenza
9.6.1 Overview
9.6.2 Europe Influenza Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Other Applications
9.7.1 Overview
9.7.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
10. Anti-Viral Therapies Market Revenue and Forecasts To 2027 – Geographical Analysis
10.1 Europe Anti-Viral Therapies Market Revenue and Forecasts To 2027
10.1.1 Overview
10.1.2 Europe: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.3 Europe: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.4 Europe: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.5 Europe: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.1.6 Europe: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
10.1.7 Germany: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Germany: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Germany: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.7.3 Germany: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.7.4 Germany: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.1.8 UK: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.1 UK: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.2 UK: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.8.3 UK: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.8.4 UK: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.1.9 France: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.1 France: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.2 France: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.9.3 France: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.9.4 France: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.1.10 Spain: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.1 Spain: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.2 Spain: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.10.3 Spain: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.10.4 Spain: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.1.11 Italy: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.1 Italy: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.2 Italy: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.11.3 Italy: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.11.4 Italy: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
11. Impact of COVID-19 Pandemic on Europe Anti-viral therapies Market
11.1 Europe: Impact Assessment of COVID-19 Pandemic
12. Company Profiles
12.1 GlaxoSmithKline plc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 S WOT Analysis
12.1.6 Key Developments
12.2 AstraZeneca
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. HOFFMANN-LA ROCHE LTD.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 AbbVie Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Johnson and Johnson Services, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Anti-Viral Therapies Market Revenue and Forecasts To 2027, By Type (US$ Mn)
Table 2. Europe Anti-Viral Therapies Market Revenue and Forecasts To 2027, By Mechanism of Action (US$ Mn)
Table 3. Europe Anti-Viral Therapies Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 4. Europe Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 5. Europe Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 6. Europe Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 7. Germany Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 8. Germany Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 9. Germany Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 10. UK Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 11. UK Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 12. UK Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 13. France Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 14. France Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 15. France Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 16. Spain Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 17. Spain Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 18. Spain Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 19. Italy Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 20. Italy Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 21. Italy Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 22. Glossary of Terms, Anti-Viral Therapies Market
LIST OF FIGURES
Figure 1. Anti-Viral Therapies Market Segmentation
Figure 2. Europe Anti-Viral Therapies Market Overview
Figure 3. Branded Drugs Segment Held Largest Share of Anti-Viral Therapies Market
Figure 4. UK is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Europe Anti-Viral Therapies Market - Leading Country Markets (US$ Mn)
Figure 6. Anti-Viral Therapies Market - North America PEST Analysis
Figure 7. Anti-Viral Therapies Market - Europe PEST Analysis
Figure 8. Anti-Viral Therapies Market Impact Analysis of Driver and Restraints
Figure 9. Europe Anti-viral therapies Market – Revenue Forecasts and Analysis – 2019- 2027
Figure 10. Europe Anti-Viral Therapies Market, By Type 2019 & 2027 (%)
Figure 11. Europe Generic Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Europe Branded Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Europe Anti-Viral Therapies Market, by Mechanism of Action 2019 & 2027 (%)
Figure 14. Europe Nucleotide Polymerase Inhibitor Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Europe Reverse Transcriptase Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Europe Protease Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Europe Anti-Viral Therapies Market, By Application 2019 & 2027 (%)
Figure 19. Europe HIV Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Europe Hepatitis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Europe Herpes Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Europe Influenza Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Europe: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)
Figure 25. Europe Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)
Figure 26. Europe: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
Figure 27. Germany: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 28. UK: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 29. France: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Spain: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 31. Italy: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 32. Impact of COVID-19 Pandemic in Europe Country Markets
The List of Companies - Europe Anti-Viral Therapies Market
- AbbVie Inc.
- GlaxoSmithKline plc
- AstraZeneca
- F. HOFFMANN-LA ROCHE LTD
- Johnson and Johnson Services, Inc.
- It provides understanding of the Europe anti-viral therapies market landscape and identifies anti-viral therapies market segments that are most likely to guarantee a strong return.
- It guides stay ahead of the race by comprehending the ever-changing competitive market landscape.
- It helps efficiently plan merger and acquisition, and partnership deals in the anti-viral therapies market in Europe by identifying market segments with the most promising probable sales.
- It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of the market performance of various segments.
- It provides revenue forecast of the market based on various segments for the period from 2019 to 2027.